Patents by Inventor Michael Kaplitt
Michael Kaplitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170182191Abstract: One embodiment is directed to a method for controllably managing pain in the afferent nervous system of a patient having a targeted tissue structure that has been genetically modified to have light sensitive protein, comprising: providing a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure, a light source configured to provide light to the light delivery element, and a controller operatively coupled to light source, wherein the targeted tissue structure comprises a sensory neuron of the patient; and automatically operating the controller to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.Type: ApplicationFiled: July 29, 2015Publication date: June 29, 2017Applicant: Circuit Therapeutics, Inc.Inventors: Christopher L. Towne, Michael Kaplitt, Scott Delp, Karl Deisseroth, David Angeley, Greg Stahler, Dan Andersen, David C. Lundmark
-
Publication number: 20160030765Abstract: One embodiment is directed to a system for controllably managing pain in the afferent nervous system of a patient having a targeted tissue structure that has been genetically modified to have light sensitive protein, comprising a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure; a light source configured to provide light to the light delivery element; and a controller operatively coupled to light source; wherein the targeted tissue structure comprises a sensory neuron of the patient; and wherein the controller is configured to be automatically operated to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.Type: ApplicationFiled: July 29, 2015Publication date: February 4, 2016Applicant: Circuit Therapeutics, Inc.Inventors: Christopher L. Towne, Michael Kaplitt, Scott Delp, Karl Deisseroth, David Angeley, Greg Stahler, Dan Andersen, David C. Lundmark
-
Publication number: 20150360050Abstract: One embodiment is directed to a method for controllably managing motor function in the central nervous system of a patient having a targeted tissue structure that has been genetically modified to have light sensitive protein, comprising: providing a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure, a light source configured to provide light to the light delivery element, and a controller operatively coupled to light source, wherein the targeted tissue structure is a portion of the basal ganglia of the patient; and automatically operating the controller to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.Type: ApplicationFiled: June 11, 2015Publication date: December 17, 2015Applicant: CIRCUIT THERAPEUTICS, INC.Inventors: MICHAEL KAPLITT, DAN ANDERSEN
-
Publication number: 20150360049Abstract: One embodiment is directed to a system for controllably managing motor function in the central nervous system of a patient having a targeted tissue structure that has been genetically modified to have light sensitive protein, comprising a light delivery element configured to direct radiation to at least a portion of a targeted tissue structure; a light source configured to provide light to the light delivery element; and a controller operatively coupled to light source; wherein the targeted tissue structure is a portion of the basal ganglia of the patient; and wherein the controller is configured to be automatically operated to illuminate the targeted tissue structure with radiation such that a membrane potential of cells comprising the targeted tissue structure is modulated at least in part due to exposure of the light sensitive protein to the radiation.Type: ApplicationFiled: June 11, 2015Publication date: December 17, 2015Applicant: Circuit Therapeutics, Inc.Inventors: Michael Kaplitt, Dan Andersen
-
Patent number: 8642341Abstract: The invention provides materials and methods for p11-mediated therapy of psychiatric disorders. The invention provides vectors for increasing p11 expression and methods of treating a mammal with one or more symptoms of a psychiatric disorder. The invention also provides methods for improving a mammal's responsiveness to treatment for a psychiatric disorder. The invention further provides model animals for depression and depression therapy.Type: GrantFiled: October 31, 2008Date of Patent: February 4, 2014Assignee: Cornell UniversityInventors: Michael Kaplitt, Brian L. Alexander
-
Publication number: 20120039991Abstract: The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding an inhibitor of apoptosis protein (IAP) to cells in the region.Type: ApplicationFiled: August 17, 2011Publication date: February 16, 2012Applicant: NEUROLOGIX, INC.Inventors: Michael Kaplitt, Serguei Moussatov
-
Patent number: 8017385Abstract: The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding an inhibitor of apoptosis protein (IAP) to cells in the region.Type: GrantFiled: October 21, 2005Date of Patent: September 13, 2011Assignee: Neurologix, Inc.Inventors: Michael Kaplitt, Serguei Moussatov
-
Publication number: 20110207802Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.Type: ApplicationFiled: April 27, 2011Publication date: August 25, 2011Applicant: NEUROLOGIX, INC.Inventors: Matthew During, Michael Kaplitt
-
Patent number: 7955595Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.Type: GrantFiled: January 11, 2010Date of Patent: June 7, 2011Assignee: Neurologix, Inc.Inventors: Matthew During, Michael Kaplitt
-
Publication number: 20100263065Abstract: The invention provides materials and methods for p11-mediated therapy of psychiatric disorders. The invention provides vectors for increasing p11 expression and methods of treating a mammal with one or more symptoms of a psychiatric disorder. The invention also provides methods for improving a mammal's responsiveness to treatment for a psychiatric disorder. The invention further provides model animals for depression and depression therapy.Type: ApplicationFiled: October 31, 2008Publication date: October 14, 2010Applicant: Cornell UniversityInventors: Michael Kaplitt, Brian L. Alexander
-
Publication number: 20100143458Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.Type: ApplicationFiled: January 11, 2010Publication date: June 10, 2010Applicant: NEUROLOGIX, INC.Inventors: Matthew During, Michael Kaplitt
-
Patent number: 7695959Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.Type: GrantFiled: March 16, 2004Date of Patent: April 13, 2010Assignee: Neurologix, Inc.Inventors: Matthew During, Michael Kaplitt
-
Patent number: 7645446Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the subthalmic nucleus of the basal ganglia, mesaphilia and thalamus.Type: GrantFiled: March 16, 2004Date of Patent: January 12, 2010Assignee: Neurologix, Inc.Inventors: Matthew During, Michael Kaplitt
-
Publication number: 20070059290Abstract: The present invention describes a method of identifying inducible genetic regulatory sequences that can control the transcription of specific gene transcripts. Methods of using inducible genetic regulatory sequences are also discussed. In particular, the genetic regulatory sequences of the present invention can modulate the transcription of a nucleic acid transcript in vivo.Type: ApplicationFiled: October 3, 2006Publication date: March 15, 2007Inventors: Michael Kaplitt, Matthew During, Andres Lozano
-
Publication number: 20060228776Abstract: The invention provides methods and compositions of an upstream regulatory element (PINK-1 promoter) operably linked to an expressible gene, wherein the expression of the expressible gene is driven by the upstream regulatory element.Type: ApplicationFiled: October 21, 2005Publication date: October 12, 2006Applicant: NEUROLOGIX, INC.Inventors: Michael Kaplitt, Serguei Moussatov
-
Publication number: 20060210538Abstract: The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding an inhibitor of apoptosis protein (IAP) to cells in the region.Type: ApplicationFiled: October 21, 2005Publication date: September 21, 2006Applicant: NEUROLOGIX, INC.Inventors: Michael Kaplitt, Serguei Moussatov
-
Publication number: 20060129126Abstract: A fluid infusion device and a method of using the same. The device includes an outer, flexible guide catheter having a distal end for introduction beneath the skull of a patient and a proximal end remaining external of the patient. A flexible infusion fiber is located within the guide catheter and has a distal end extending outwardly from the guide catheter to be located in a target area within the patient's brain. The infusion fiber can be fixed or axially movable within the guide catheter. In the latter embodiment, the proximal end of the infusion fiber extending outwardly from the guide catheter can be manipulated to locate the distal end of the infusion fiber in the target area. An infusion pump is connected to the proximal end of the infusion fiber to infuse a minute quantity of fluid at an extremely low flow rate into the brain of the patient.Type: ApplicationFiled: November 16, 2005Publication date: June 15, 2006Inventors: Michael Kaplitt, Matthew During
-
Publication number: 20060099179Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the subthalmic nucleus of the basal ganglia, mesaphilia and thalmus.Type: ApplicationFiled: March 16, 2004Publication date: May 11, 2006Applicant: NEUROLOGIX, INC.Inventors: Matthew During, Michael Kaplitt
-
Publication number: 20050025746Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.Type: ApplicationFiled: March 16, 2004Publication date: February 3, 2005Applicant: NEUROLOGIX, INC.Inventors: Matthew During, Michael Kaplitt
-
Patent number: 6780409Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the subthalmic nucleus of the basal ganglia, mesaphilia and thalmus.Type: GrantFiled: May 23, 2001Date of Patent: August 24, 2004Assignees: Thomas Jefferson University, Neurologix, Inc.Inventors: Matthew J. During, Michael Kaplitt